BCL2 and B-cell chronic lymphocytic leukemia: Venetoclax specifically targeting BCL-2 has been approved for treatment of chronic lymphocytic leukemia, and several other BH3 mimetics, such as navitoclax targeting BCL-2, BCL-xL, and BCL-w, are currently under clinical trials for several hematological malignancies [18].